Placental Growth Factor (PlGF) Is a Surrogate Marker in Preeclamptic Hypertension

Teixeira, Patrícia Gonçalves; Cabral, Antônio Carlos Vieira; Andrade, Sílvia Passos; Reis, Zilma Silveira Nogueira; Cruz, Lívia Pieroni Barroso da; Pereira, Jonas Carlos Campos; Martins, Breno Oliveira de Barcelos; Rezende, Cézar Alencar de Lima

doi:10.1080/10641950701825937

Cited by 34 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, we found high inter- and intra-plate CV% with the manual method, which has been corroborated by others [19,20,21]. A recent paper has compared the Quantikine ELISA to a third assay for detection of PlGF, the Beckman Coulter Access PlGF immunoassay, and although finding a general agreement between these two methods, the concentrations were generally lower in the Quantikine ELISA than the Access assay [21].…”

Section: Discussionsupporting

confidence: 88%

A Comparison of Two Immunoassay Methods for the Measurement of Maternal Serum Placental Growth Factor in Early Pregnancy

Cowans

Kisanga²,

Khan³

et al. 2012

Fetal Diagn Ther

View full text Add to dashboard Cite

Objectives: To compare the DELFIA Xpress and Quantikine ELISA placental growth factor (PlGF) immunoassay platforms by analysing the same set of early first-trimester maternal serum samples from cases with trisomy 21 and euploid controls. Methods: Thirty-seven trisomy 21 cases and 243 euploid control serum samples, drawn at 8⁺⁰ to 10⁺⁶ weeks of gestation, were reanalysed by Quantikine PlGF ELISA following original analysis on the DELFIA Xpress platform. Results: PlGF levels increased with gestation in the euploid controls when measured on both platforms, although raw levels were in general lower on the DELFIA Xpress. After conversion to multiples of the median (MoMs), PlGF was increased in trisomy 21 cases when measured on the DELFIA Xpress platform (euploid: 1.00 MoM, trisomy 21: 1.32 MoM, p < 0.0001) but unchanged when measured on the Quantikine ELISA (euploid: 1.01 MoM, trisomy 21: 1.06 MoM, p = 0.84). Conclusions: Discrepancies exist in the measurement of PlGF when performed on these different platforms, which may to some extent contribute to the inconsistencies found in the literature with regard to PlGF in trisomy 21 pregnancies.

show abstract

Section: Discussionsupporting

confidence: 88%

A Comparison of Two Immunoassay Methods for the Measurement of Maternal Serum Placental Growth Factor in Early Pregnancy

Cowans

Kisanga²,

Khan³

et al. 2012

Fetal Diagn Ther

View full text Add to dashboard Cite

show abstract

“…Indeed, patients with preeclampsia have higher plasma concentrations of sVEGFR-1 [7][8][9][10]12,13,16,21,22,24,27,29,29,31,33,34,39,41,42,46,48] and sEng [25,30,[34][35][36]42,45,46,48] and lower plasma concentration of VEGF [8,49] and PlGF [3,5,6,8,11,12,14,27,29,33,38,39,41,42,46,[49][50][51] than patients with normal pregnancies at the time of the clinical diagnosis of preeclampsia. These differences have been observed even before the clinical presentation of the disease.…”

Section: Introductionmentioning

confidence: 99%

A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia

Kusanovic¹,

Romero²,

Chaiworapongsa³

et al. 2009

DJMF

View full text Add to dashboard Cite

OBJECTIVE-Changes in the maternal plasma concentrations of angiogenic (such as PlGF and VEGF) and anti-angiogenic factors (such as sEng and sVEGFR-1) precede the clinical presentation of preeclampsia. This study was conducted to examine the role of maternal plasma PlGF, sEng and sVEGFR-1 concentrations in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.METHODS-This longitudinal cohort study included 1,622 consecutive singleton pregnant women. Plasma samples were obtained in early pregnancy (6-15 weeks) and midtrimester (20-25 weeks). Maternal plasma PlGF, sEng and sVEGFR-1 concentrations were determined using sensitive and specific immunoassays. The primary outcome was the development of preeclampsia. Secondary outcomes included term, preterm and early-onset preeclampsia. Receiving operating characteristic (ROC) curves, sensitivity, specificity, positive and negative likelihood ratios, and multivariable logistic regression were used for statistical analyses. A p-value of <0.05 was considered significant. RESULTS-1)The prevalence of preeclampsia, term, preterm (<37 weeks) and early-onset preeclampsia (<34 weeks) was 3.8% (62/1,622), 2.5% (40/1,622), 1.4% (22/1,622) and 0.6% (9/1,622), respectively; 2) Higher likelihood ratios were provided by ratios of midtrimester plasma concentrations of PlGF, sEng, and sVEGFR-1 than single analytes; 3) Individual angiogenic and anti-angiogenic factors did not perform well in the identification of preeclampsia as a whole; in particular, they perform poorly in the prediction of term preeclampsia; 4) In contrast, a NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript combination of these analytes such as the PlGF/sEng ratio, its delta and slope had the best predictive performance with a sensitivity of 100%, a specificity of 98%-99%, and likelihood ratios for a positive test of 57.6, 55.6 and 89.6, respectively, for predicting early-onset preeclampsia. CONCLUSIONS-1)The PlGF/sEng ratio and its delta and slope had an excellent predictive performance for the prediction of early-onset preeclampsia, with very high likelihood ratios for a positive test result and very low likelihood ratios for a negative test result; and 2) Although the positive likelihood ratios are high and the positive predictive values low, the number of patients needed to be closely followed is 4:1 for the PlGF/sEng ratio and 3:1 for the slope of PlF/sEng.

show abstract

“…Despite differing perceptions on the etiology of PE, as well as differing hypotheses regarding the roles of proteins involved in angiogenesis, results from case-control studies in Table I demonstrated two important findings: (1) sFlt1 serum concentrations and sEng concentrations were significantly elevated in women with destined to develop PE than controls [34,45,[49][50][51][52][53][54][55][56][57][58]89], and (2) VEGF levels were lower in women with PE than controls; significantly decreased circulating levels of free VEGF and PLGF resulted in endothelial dysfunction in vitro in women who developed PE [49,60].…”

Section: Resultsmentioning

confidence: 99%

Markers of preeclampsia and the relationship to cardiovascular disease: review of the twenty-first century literature

Gastrich

Faro

Rosen

2010

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

show abstract

Placental Growth Factor (PlGF) Is a Surrogate Marker in Preeclamptic Hypertension

Abstract: These results indicate that PlGF is related to MAP in pregnant women.

Cited by 34 publications

References 25 publications

A Comparison of Two Immunoassay Methods for the Measurement of Maternal Serum Placental Growth Factor in Early Pregnancy

A Comparison of Two Immunoassay Methods for the Measurement of Maternal Serum Placental Growth Factor in Early Pregnancy

A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia

Markers of preeclampsia and the relationship to cardiovascular disease: review of the twenty-first century literature

Contact Info

Product

Resources

About